Merck/Bayer’s Vericiguat Outcomes Data Less Impressive On Fuller Disclosure
Executive Summary
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
You may also be interested in...
Merck & Co. Pushes Back On Modest Projections For Verquvo
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients
Detailed data for omecamtiv mecarbil at AHA show a slim overall benefit, but Cytokinetics highlighted its effects in sicker patients and investigators emphasized the drug’s impact on reduced hospitalizations.
Amgen/Cytokinetics Phase III Heart Failure Data Are Below Expectations
Analysts considered the Phase III GALACTIC-HF study of omecamtiv mecarbil a failure but some anticipated that detailed data to be presented next month could at least partially redeem the drug.